Literature DB >> 6118067

Familial tardive dyskinesia.

R Yassa, J Ananth.   

Abstract

The authors surveyed 500 inpatients receiving long-term neuroleptics; 8 had first-degree family members who were also being treated with long-term neuroleptics and suffering from a psychiatric disorder. The 8 patient-relative pairs showed concordance for the presence or absence of tardive dyskinesia.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6118067     DOI： 10.1176/ajp.138.12.1618

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  11 in total

Review 1.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

2.  Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.

Authors:  Renan P Souza; Vincenzo de Luca; Gary Remington; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Albert H C Wong
Journal:  Psychopharmacology (Berl)       Date:  2010-04-06       Impact factor: 4.530

3.  Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.

Authors:  James J Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L Pratt; Corey R Quackenbush; Daniel E Adkins; Edwin van den Oord; Molly A Bogue; Hyuna Yang; Wei Wang; David W Threadgill; Fernando Pardo-Manuel de Villena; Howard L McLeod; Patrick F Sullivan
Journal:  Mamm Genome       Date:  2011-12-30       Impact factor: 2.957

4.  No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.

Authors:  Hiroko Hori; Takahiro Shinkai; Chima Matsumoto; Osamu Ohmori; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

5.  A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.

Authors:  Huei-Ting Tsai; Stanley N Caroff; Del D Miller; Joseph McEvoy; Jeffrey A Lieberman; Kari E North; T Scott Stroup; Patrick F Sullivan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

6.  No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients.

Authors:  Young-Min Park; Seung-Gul Kang; Jung-Eun Choi; Yong-Ku Kim; Seung-Hyun Kim; Ji-Young Park; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2011-03-10       Impact factor: 2.505

Review 7.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

8.  No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia.

Authors:  Heon-Jeong Lee; Seung-Gul Kang; Jung-Eun Choi; Young-Min Park; Se-Won Lim; Min Kyu Rhee; Seung-Hyun Kim; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

9.  Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis.

Authors:  James J Crowley; Yunjung Kim; Alan B Lenarcic; Corey R Quackenbush; Cordelia J Barrick; Daniel E Adkins; Ginger S Shaw; Darla R Miller; Fernando Pardo-Manuel de Villena; Patrick F Sullivan; William Valdar
Journal:  Genetics       Date:  2013-11-15       Impact factor: 4.562

10.  Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis.

Authors:  Clement C Zai; Frankie H Lee; Arun K Tiwari; Justin Y Lu; Vincenzo de Luca; Miriam S Maes; Deanna Herbert; Anashe Shahmirian; Sheraz Y Cheema; Gwyneth C Zai; Anupama Atukuri; Michael Sherman; Sajid A Shaikh; Maria Tampakeras; Natalie Freeman; Nicole King; Daniel J Müller; Lior Greenbaum; Bernard Lerer; Aristotle N Voineskos; Steven G Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; Gary Remington; James L Kennedy
Journal:  Front Pharmacol       Date:  2018-09-18       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.